Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases

NCT07873931 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07873931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07873931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
January 31, 2033
Enrollment
60 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathies, lupus nephritis, rheumatoid arthritis, sjögren's disease, systemic lupus erythematosus, systemic sclerosis